Shiloh
Editor, Senior Moderator
Source: http://www.starbulletin.com/business/20090825_Company_begins_trials_on_dengue_vaccine.html
Company begins trials on dengue vaccine
By Star-Bulletin staff
POSTED: 01:30 a.m. HST, Aug 25, 2009
Hawaii Biotech Inc. has begun Phase 1 clinical trials on a potential dengue fever vaccine it developed.
The first phase of the trial on its monovalent vaccine candidate is being conducted at the St. Louis University Vaccine Development Center. It is a double-blind, placebo-controlled, dose-escalation safety study on healthy participants, said Elliot Parks, Hawaii Biotech president and chief executive officer.
"This dengue clinical study is an important milestone in Hawaii Biotech's maturation as a clinical stage company," Parks said. "It will also prepare us for the initial clinical testing of Hawaii Biotech's tetravalent dengue vaccine."
The trial is designed to assess the potential vaccine's safety, determine a range of doses and identify potential side effects.
Results are expected within a year.
Dengue fever, also known as "break-bone fever," is an infectious disease common in tropical and subtropical countries around the world. Of the estimated 3.5 billion people who live in these climes, about 100 million are infected with dengue annually.
Company begins trials on dengue vaccine
By Star-Bulletin staff
POSTED: 01:30 a.m. HST, Aug 25, 2009
Hawaii Biotech Inc. has begun Phase 1 clinical trials on a potential dengue fever vaccine it developed.
The first phase of the trial on its monovalent vaccine candidate is being conducted at the St. Louis University Vaccine Development Center. It is a double-blind, placebo-controlled, dose-escalation safety study on healthy participants, said Elliot Parks, Hawaii Biotech president and chief executive officer.
"This dengue clinical study is an important milestone in Hawaii Biotech's maturation as a clinical stage company," Parks said. "It will also prepare us for the initial clinical testing of Hawaii Biotech's tetravalent dengue vaccine."
The trial is designed to assess the potential vaccine's safety, determine a range of doses and identify potential side effects.
Results are expected within a year.
Dengue fever, also known as "break-bone fever," is an infectious disease common in tropical and subtropical countries around the world. Of the estimated 3.5 billion people who live in these climes, about 100 million are infected with dengue annually.